CVTX to continue Ranexa Phase III

CV Therapeutics (CVTX) said a DSMB recommended continuing the international Phase III MERLIN TIMI-36 trial of Ranexa ranolazine as first-line therapy in about 6,500 patients with non-ST elevation acut...